MedTrace Logo

Seroprevalence of SARS-Cov-2 Antibodies in Children

NCT04347408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2023-12-07

Study results available
· View outcomes & findings →

Summary

It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to SARS-CoV-2.

Conditions

  • COVID
  • Corona Virus Infection
  • Multisystem Inflammatory Syndrome in Children

Interventions

DIAGNOSTIC_TEST

Covid-19 Antibody testing (IgG and IgM)

Antibody testing for previous exposure to Covid-19

OTHER

Blood Storage

Storage of blood for multi-omics analysis

Sponsors & Collaborators

  • Belfast Health and Social Care Trust

    collaborator OTHER

  • Queen's University, Belfast

    lead OTHER

Principal Investigators

  • Thomas Waterfield, BMBCh · Queen's University, Belfast

Eligibility

Min Age
1 Month
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-06
Primary Completion
2021-12-01
Completion
2023-11-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04347408 on ClinicalTrials.gov